Vicky A. Appleman

713 total citations · 1 hit paper
12 papers, 186 citations indexed

About

Vicky A. Appleman is a scholar working on Immunology, Oncology and Cancer Research. According to data from OpenAlex, Vicky A. Appleman has authored 12 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 8 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Vicky A. Appleman's work include interferon and immune responses (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immune cells in cancer (3 papers). Vicky A. Appleman is often cited by papers focused on interferon and immune responses (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immune cells in cancer (3 papers). Vicky A. Appleman collaborates with scholars based in United States and Costa Rica. Vicky A. Appleman's co-authors include Adnan O. Abu‐Yousif, Michelle L. Ganno, David Lok, Jianing Wang, Walid S. Kamoun, Pere Dosta, Natalie Artzi, Michaela Prado, Shiran Ferber and Steven Langston and has published in prestigious journals such as Journal of Clinical Oncology, Nature Nanotechnology and Cancer Research.

In The Last Decade

Vicky A. Appleman

11 papers receiving 184 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles

2023 103 citations Pere Dosta, Steven Langston et al. Nature Nanotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vicky A. Appleman United States	6	137	71	46	41	30	12	186
Jillian Rosenberg United States	7	139 1.0×	96 1.4×	51 1.1×	125 3.0×	42 1.4×	9	293
Katarzyna Olesek Netherlands	8	188 1.4×	108 1.5×	20 0.4×	48 1.2×	22 0.7×	10	254
Gabriela N. Johnson United States	3	89 0.6×	81 1.1×	26 0.6×	61 1.5×	17 0.6×	5	170
Yariv Greenshpan Israel	9	51 0.4×	90 1.3×	93 2.0×	45 1.1×	65 2.2×	18	243
Yohan Gerber-Ferder France	3	120 0.9×	39 0.5×	23 0.5×	37 0.9×	12 0.4×	4	148
Stefano Di Cecca Italy	10	109 0.8×	65 0.9×	74 1.6×	61 1.5×	20 0.7×	13	226
Taylor L. Sheehy United States	3	222 1.6×	127 1.8×	58 1.3×	56 1.4×	58 1.9×	4	278
William Crowe United States	6	200 1.5×	125 1.8×	52 1.1×	63 1.5×	105 3.5×	8	341
Sarah E. Blatt United States	4	204 1.5×	96 1.4×	18 0.4×	114 2.8×	23 0.8×	7	299
Justin J. King Canada	10	109 0.8×	144 2.0×	11 0.2×	41 1.0×	30 1.0×	13	274

Countries citing papers authored by Vicky A. Appleman

Since Specialization

Citations

This map shows the geographic impact of Vicky A. Appleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicky A. Appleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicky A. Appleman more than expected).

Fields of papers citing papers by Vicky A. Appleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicky A. Appleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicky A. Appleman. The network helps show where Vicky A. Appleman may publish in the future.

Co-authorship network of co-authors of Vicky A. Appleman

This figure shows the co-authorship network connecting the top 25 collaborators of Vicky A. Appleman. A scholar is included among the top collaborators of Vicky A. Appleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicky A. Appleman. Vicky A. Appleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Ding, Kai, Xin Tong, Radha Ramesh, et al.. (2025). Abstract 7143: Development of a peripheral dazostinag (TAK-676) activation RNASeq signature to evaluate STING pharmacodynamic modulation in human solid tumor clinical trials. Cancer Research. 85(8_Supplement_1). 7143–7143.

Porciuncula, Angelo, Vicky A. Appleman, Richard C. Gregory, et al.. (2024). Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer. Cancer Research. 84(6_Supplement). 6732–6732. 1 indexed citations

Yeo, Alan T., Rinku Pal, Shruti Rawal, et al.. (2023). Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma. Cancer Immunology Research. 11(5). 629–645. 15 indexed citations

Dosta, Pere, Steven Langston, David Lok, et al.. (2023). Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nature Nanotechnology. 18(11). 1351–1363. 103 indexed citations breakdown →

Appleman, Vicky A., Atsushi Matsuda, Michelle L. Ganno, et al.. (2022). 1153 Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500. Regular and Young Investigator Award Abstracts. A1196–A1196. 4 indexed citations

Cooper, Benjamin T., Steven J. Chmura, Jason J. Luke, et al.. (2022). TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.. Journal of Clinical Oncology. 40(16_suppl). TPS2698–TPS2698. 14 indexed citations

Appleman, Vicky A., Allison Berger, Emily Roberts, et al.. (2022). Abstract 3448: The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models. Cancer Research. 82(12_Supplement). 3448–3448. 2 indexed citations

Diamond, Jennifer R., Jason T. Henry, Gerald S. Falchook, et al.. (2022). Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors. Cancer Research. 82(12_Supplement). CT249–CT249. 7 indexed citations

Cooper, Benjamin T., Steven J. Chmura, Jason J. Luke, et al.. (2022). Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN). Cancer Research. 82(12_Supplement). CT243–CT243. 2 indexed citations

10.

Diamond, Jennifer R., Jason T. Henry, Gerald S. Falchook, et al.. (2022). Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2690–TPS2690. 17 indexed citations

11.

Yeo, Alan T., Hyun Jung Jun, Vicky A. Appleman, et al.. (2021). EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma. Oncogene. 40(15). 2682–2696. 16 indexed citations

12.

Zhou, Shuang, Vicky A. Appleman, Christopher M. Rose, et al.. (2018). Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Science Alliance. 1(3). e201800029–e201800029. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact